On November 28, the Central Epidemic Command Center (CECC) announced that Moderna's next-generation BA.4/5-adapted bivalent vaccine is scheduled to be given to children aged 6-11 who have received their primary series vaccination of Moderna or Pfizer-BNT COVID-19 vaccine. Additionally, children between 5 and 6 years of age can receive the Pfizer-BioNTech monovalent vaccine (pediatric formulation) as a booster dose to build protection. For children 5-11 years of age, a minimum interval of 12 weeks (84 days) is recommended between a booster dose and the last dose of the primary series vaccination.